Congratulations to These #ASGCT2024 Poster Presenters

View the full abstract collection

Srijana Adhikari, The Pennsylvania State University 
448. Paramyxovirus-Like Particles for Therapeutic Delivery of Proteins to Cells  

Manal Ali, Abigail Wexner Research Institute, Nationwide Children’s Hospital 
1706. Translating AAV-Delivered CRISPR-Cas13 Therapy for FSHD May Require Overcoming Size and Immune Challenges  

Saeed Anwar, University of Alberta 
723. Enhancing Antisense Oligonucleotide Efficacy with Small Molecule Oligonucleotide Activity Enhancers  

Malik Aydin, Witten/Herdecke University 
1808. Exploring Adenovirus Type 35 as Oncolytic Virus in Combination with NK-Cell Therapy as a Novel Concept in Cancer Treatment in Respiratory Disease  

Rafael A. Badell-Grau, UCSD 
845. Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIC  

Luisa Burger, German Cancer Research Centre (DKFZ) 
818. Persistent Genetic Modification of NK cells Using Non-Integrating S/MAR DNA Vectors for Cancer Immunotherapy  

Yin Caiyong, Fosun Pharma 
1409. Optogenetic Therapy UGX-201 for Patients Inflicted by Advanced Retinitis Pigmentosa: Interim Results of an Investigator Initiated Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy at First Affiliated Hospital of Soochow University  

Yahya Cheema, University of Maryland 
965. The Extracellular Matrix as a Barrier to Adeno-Associated Viral Gene Delivery  

Julieth A. Sierra Delgado, Nationwide Childrens Hospital 
619. Novel AAV Gene Therapy Candidates Show Promise In Vitro and In Vivo for Treatment of PGAP3-CDG Syndrome  

Matt P. Ercolino, VintaBio 
927. Addressing the Ex Vivo Lentivirus Black Box Warning: Reducing Risk through Engineering  

Elad Firnberg, REGENXBIO Inc. 
501. NAVIGATE: A Directed Evolution Platform for Engineering Novel Ocular and Muscle AAV Capsids in Non-Human Primates  

Lu Guo, Vitalgen BioPharma 
1098. Development of a Best-in-Class AAV Gene Therapy for Fabry Disease with Enhanced a-Gal A Expression and Cellular Uptake by Protein Engineering and Promoter Evolution  

Weirui Guo, University of Texas Southwestern Medical Center 
1000. Developmental Age Effects for AAV9/SLC6A1 Gene Therapy in Heterozygous and Homozygous SLC6A1 KO Mice  

Ulrike Jung, Sartorius Stedim Cellca GmbH 
1420. Optimization of Transient rAAV Production via HEK293 Cell Line Generation, Clone Selection and Production Process  

Rohini Kalvakuntla, Helex, Inc. 
1186. Targeting a Mutation Agnostic Regulator of PKD1 Using CRISPRCas9 for Therapeutic Intervention in Autosomal Dominant Polycystic Kidney Disease  

1693. Comprehensive Safety Analysis Using Spatial Genome Organization Data Assures Long Term Safety of Gene Editing 

Joshua B. Krueger, University of Minnesota 
1798. Armored CAR-NK Cell Therapy for Ovarian Cancer  

Sahana Kumar, University of Maryland 
1580. Mucin Targeted Gene Therapy for Asthma  

Shao-Chia Lu, Mayo Clinic 
436. FastAd- A System for the Rapid Generation of Single Adenoviruses or Complex Adenoviral Vector Libraries  

Kathrin Meyer, Nationwide Childrens Hospital 
1599. Leveraging In Silico and In Vitro Modeling for Optimization of Intrathecal AAV9 Delivery to the Brain: Validation in Nonhuman Primates and Translation to Human Rett Syndrome Patient Anatomy  

Jarin Taslem Mourosi, Catholic University of America 
438. Engineering T4 Bacteriophage Nanoparticles: A Next-Generation Paradigm for Effective Vaccine Development  

Santosh Panthi, U.S. Food and Drug Administration 
1512. Development of an Assay to Perform High-Throughput Drug Screen in HEK293 Cells to Improve AAV Vector Production 

Dawn Pinchasik, TScan Therapeutics 
1900. Trial in Progress: A Phase 1, First in Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid Tumors  

Stefano Rivella, Children's Hospital of Philadelphia 
930. Lentiviral Gene Therapy Rescues a Novel Inducible Codanin-1 KO Mouse Model of Bone Marrow Failure  

Toros Tasgin, German Cancer Research Centre (DKFZ) 
1367. Design and Characterization of Next-Generation SMAR Nanovectors for Stable Cell Modification: Towards Safer Allogeneic and Autologous Adoptive CAR-T Cell Therapy  

Kenneth W. Thompson, Thermo Fisher Scientific 
1419. Strategies for Large-Scale Plasmid DNA Complexation and Delivery to Support Commercial-Scale AAV Production  

Jon Zachary, University of Florida 
500. Structure Guided Design of the AAV9 Capsid Evading Antibodies Derived from Zolgensma Patients  

Shanzhong Zhang, Suzhou Otovia Therapeutics Co., Ltd. 
926. AAV Mediated Gene Therapy Restores Hearing in Patients with DNFB9 Deafness  

View the full abstract collection

Related Articles